학술논문

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma
Document Type
Article
Source
In: Leukemia and Lymphoma. (Leukemia and Lymphoma, 2024, 65(1):14-25)
Subject
Language
English
ISSN
10292403
10428194